Best in 7 days FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway - Han - 2022 - Journal of Cellular and Molecular Medicine US$ 21.35 Sold : Login>>
Best in 7 days Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis US$ 23.86 Sold : Login>>
Best in 7 days Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells US$ 26.47 Sold : Login>>
Best in 7 days FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells US$ 27.23 Sold : Login>>
Novo Nordisk's CagriSema Falls Short in Head-to-Head Trial vs Zepbound | Bryce Platt, PharmD posted on the topic US$ 28.71 Min. order: 1 piece ★★★★★ 4.1 (281 reviews) Sold : Login>>
Novo Nordisk's next-gen obesity drug CagriSema trial results disappoint investors US$ 24.50 Min. order: 1 piece ★★★★★ 4.8 (231 reviews) Sold : Login>>
Novo Nordisk Files NDA for CagriSema, Novel GLP-1-amylin Combination for Chronic Weight Management US$ 29.56 Min. order: 1 piece ★★★★★ 4.1 (293 reviews) Sold : Login>>
Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide US$ 29.44 Min. order: 1 piece ★★★★★ 4.0 (161 reviews) Sold : Login>>
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 4.3 (167 reviews) Sold : Login>>